On Wednesday, July 15, 2026, two GLP-1 trials were tracked, both still far from reaching pharmacy shelves. One tests whether a familiar drug class can treat a condition beyond diabetes and weight, and the other checks the basic safety of a brand new compound in people who aren't sick at all. Neither trial changes what a patient can get prescribed today. But together, they show how far the reach of GLP-1 research has extended past its original purpose.
Eli Lilly's mazdutide already has a track record in metabolic research, and this trial asks a different question: whether the drug can reduce drinking in people with alcohol use disorder. The study has completed its Phase 2 stage, though results have not yet been published. That gap matters because a completed trial with pending results is not the same as an approved use, so mazdutide for alcohol use disorder remains outside the reach of any prescription today. If the data eventually support the drug for this purpose, that would still require further trials and a formal approval process before doctors could prescribe it for drinking rather than diabetes or weight.
Daewoong Pharmaceutical's trial sits at an even earlier stage than mazdutide's alcohol study, since it is only in Phase 1 and still recruiting participants. The compound, DWRX5003, is being compared to two other formulations, DWC202502 and DWC202503, to check its safety and how the body absorbs it. Because the volunteers are healthy adults rather than patients with any diagnosed condition, this trial cannot tell us anything yet about how well the drug might treat diabetes, obesity, or any other illness. It is a first step meant to confirm the drug is safe enough to test further, and many compounds at this stage never make it to later trials or approval at all.
For readers watching the GLP-1 field for new treatment options, the takeaway is patience rather than urgency. Neither trial offers a new prescription now, and the timeline from early testing to pharmacy availability typically runs several years, if it happens at all. I would suggest checking back on trial records periodically rather than expecting fast movement, and talking with a doctor about currently approved GLP-1 options if immediate treatment is the goal. Watching a trial's progress is a reasonable habit, but it should not delay decisions about care that is available today.
Key details
Eli Lilly is testing mazdutide for alcohol use disorder, but it isn't available yet.
Daewoong is now recruiting healthy adults for a Phase 1 safety trial of DWRX5003.
Read this on GLP1Laws: https://glp1laws.com/patient-lens/access-roundup-2026-07-15